Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Japanese pharmaceutical firm Astellas is shuttering three R&D sites in the U.S. and Japan as part of a broad overhaul of its research network. Two of the sites will be closed this year. Both came into its fold through acquisitions: the Farmingdale, N.Y., research facility of Astellas subsidiary OSI Pharmaceuticals, bought in 2010, and the Redwood City, Calif., labs of Perseid Therapeutics, purchased in 2011. In 2015, the doors will close on Astellas’ Kashima research facility in Osaka, and in-house fermentation research will end. Astellas says some functions from the three shuttered sites will be transferred to its R&D facility in Tsukuba.
This article has been sent to the following recipient: